Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 125117
Published online Nov 24, 2026. doi: 10.5306/wjco.125117
Published online Nov 24, 2026. doi: 10.5306/wjco.125117
Table 1 Baseline characteristics by disease-free survival event status, n (%)
| Characteristic | All patients (n = 440) | No DFS event (n = 281) | DFS event (n = 159) | P value |
| Age, years | 64.00 (56.00, 70.00) | 64.00 (58.00, 70.00) | 65.00 (55.50, 72.00) | 0.398 |
| Sex | ||||
| Male | 253 (57.5) | 174 (61.9) | 79 (49.7) | 0.017 |
| Female | 187 (42.5) | 107 (38.1) | 80 (50.3) | |
| Body mass index | 22.79 (20.66, 24.77) | 22.59 (20.59, 24.67) | 23.03 (20.80, 24.90) | 0.262 |
| ASA classification | ||||
| I-II | 367 (83.4) | 246 (87.5) | 121 (76.1) | 0.003 |
| III or higher | 73 (16.6) | 35 (12.5) | 38 (23.9) | |
| Tumor site | ||||
| Right-sided colon | 111 (25.2) | 66 (23.5) | 45 (28.3) | 0.465 |
| Left-sided colon | 112 (25.5) | 71 (25.3) | 41 (25.8) | |
| Rectum | 217 (49.3) | 144 (51.2) | 73 (45.9) | |
| Preoperative bowel obstruction | ||||
| No | 416 (94.5) | 271 (96.4) | 145 (91.2) | 0.035 |
| Yes | 24 (5.5) | 10 (3.6) | 14 (8.8) | |
| Preoperative CEA, ng/mL | 3.84 (2.08, 9.93) | 3.46 (2.00, 8.33) | 4.42 (2.25, 11.34) | 0.065 |
| Preoperative CA19-9, U/mL | 6.53 (2.50, 16.66) | 5.63 (2.44, 13.37) | 8.72 (2.79, 28.22) | 0.009 |
| Preoperative albumin, g/L | 38.00 (35.00, 40.40) | 37.90 (34.90, 40.20) | 38.30 (35.25, 40.70) | 0.428 |
| Neutrophil-to-lymphocyte ratio | 2.04 (1.55, 2.92) | 2.02 (1.51, 2.86) | 2.07 (1.59, 3.08) | 0.255 |
| pT4 subtype | ||||
| pT4a | 329 (74.8) | 215 (76.5) | 114 (71.7) | 0.316 |
| pT4b | 111 (25.2) | 66 (23.5) | 45 (28.3) | |
| pN stage | ||||
| pN0 | 155 (35.2) | 120 (42.7) | 35 (22.0) | < 0.001 |
| pN1 | 179 (40.7) | 106 (37.7) | 73 (45.9) | |
| pN2 | 106 (24.1) | 55 (19.6) | 51 (32.1) | |
| Tumor size | ||||
| ≤ 5 cm | 274 (62.3) | 172 (61.2) | 102 (64.2) | 0.611 |
| > 5 cm | 166 (37.7) | 109 (38.8) | 57 (35.8) | |
| Histological type | ||||
| Conventional adenocarcinoma | 405 (92.0) | 263 (93.6) | 142 (89.3) | 0.244 |
| Mucinous adenocarcinoma | 17 (3.9) | 8 (2.8) | 9 (5.7) | |
| Signet-ring cell carcinoma or other special type | 18 (4.1) | 10 (3.6) | 8 (5.0) | |
| Differentiation grade | ||||
| Moderate/well differentiation | 365 (83.0) | 244 (86.8) | 121 (76.1) | 0.006 |
| Poor differentiation | 75 (17.0) | 37 (13.2) | 38 (23.9) | |
| Lymphovascular invasion | ||||
| Negative | 278 (63.2) | 191 (68.0) | 87 (54.7) | 0.008 |
| Positive | 162 (36.8) | 90 (32.0) | 72 (45.3) | |
| Perineural invasion | ||||
| Negative | 287 (65.2) | 192 (68.3) | 95 (59.7) | 0.087 |
| Positive | 153 (34.8) | 89 (31.7) | 64 (40.3) |
Table 2 Final Cox model after least absolute shrinkage and selection operator selection
| Term or comparison | Coefficient | SE | HR (95%CI) | P value |
| ln(CA19-9 + 1) | 0.122032 | 0.050061 | 1.130 (1.024-1.246) | 0.015 |
| Female vs male | 0.309278 | 0.162503 | 1.362 (0.991-1.873) | 0.057 |
| ASA III or higher vs ASA I-II | 0.472620 | 0.195395 | 1.604 (1.094-2.353) | 0.016 |
| Preoperative bowel obstruction: Yes vs no | 0.423322 | 0.301651 | 1.527 (0.845-2.758) | 0.161 |
| Poor vs moderate/well differentiation | 0.386838 | 0.191337 | 1.472 (1.012-2.142) | 0.043 |
| Lymphovascular invasion: Positive vs negative | 0.249850 | 0.170485 | 1.284 (0.919-1.793) | 0.143 |
| pN1 vs pN0 | 0.565960 | 0.211612 | 1.761 (1.163-2.666) | 0.007 |
| pN2 vs pN0 | 0.696416 | 0.228978 | 2.007 (1.281-3.143) | 0.002 |
Table 3 Discrimination of the proposed model and TNM-only comparator
| Model | Measure | Estimate | 95%CI |
| Proposed model | Harrell C-index | 0.670 | 0.628-0.711 |
| Conditional bootstrap optimism-corrected C-index | 0.652 | Not estimated | |
| Time-dependent AUC at 36 months | 0.704 | 0.650-0.756 | |
| Time-dependent AUC at 60 months | 0.717 | 0.644-0.780 | |
| TNM-only comparator | Harrell C-index | 0.609 | 0.567-0.650 |
| Conditional bootstrap optimism-corrected C-index | 0.598 | Not estimated | |
| Time-dependent AUC at 36 months | 0.621 | 0.564-0.677 | |
| Time-dependent AUC at 60 months | 0.542 | 0.458-0.626 |
- Citation: Zeng QY, Wu XL, Hang QR, Chen RP, Wang GQ. Development and internal validation of a disease-free survival model after radical resection of pathological T4 colorectal adenocarcinoma. World J Clin Oncol 2026; 17(11): 125117
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/125117.htm
- DOI: https://dx.doi.org/10.5306/wjco.125117